Organic Cation Transporters in Psychiatric Disorders.
Antidepressant
Anxiety
Autism spectrum disorder
Depression
Dopamine
Dopamine transporter
Norepinephrine
Norepinephrine transporter
Organic cation transporter
Plasma membrane monoamine transporter
Psychiatric disorder
Serotonin
Serotonin transporter
Journal
Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
21
7
2021
medline:
29
10
2021
entrez:
20
7
2021
Statut:
ppublish
Résumé
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed medications for psychiatric disorders, yet they leave the majority of patients without full symptom relief. Therefore, a major research challenge is to identify novel targets for the improved treatment of these disorders. SSRIs act by blocking the serotonin transporter (SERT), the high-affinity, low-capacity, uptake-1 transporter for serotonin. Other classes of antidepressant work by blocking the norepinephrine or dopamine transporters (NET and DAT), the high-affinity, low-capacity uptake-1 transporters for norepinephrine and dopamine, or by blocking combinations of SERT, NET, and DAT. It has been proposed that uptake-2 transporters, which include organic cation transporters (OCTs) and the plasma membrane monoamine transporter (PMAT), undermine the therapeutic utility of uptake-1 acting antidepressants. Uptake-2 transporters for monoamines have low affinity for these neurotransmitters, but a high capacity to transport them. Thus, activity of these transporters may limit the increase of extracellular monoamines thought to be essential for ultimate therapeutic benefit. Here preclinical evidence supporting a role for OCT2, OCT3, and PMAT in behaviors relevant to psychiatric disorders is presented. Importantly, preclinical evidence revealing these transporters as targets for the development of novel therapeutics for psychiatric disorders is discussed.
Identifiants
pubmed: 34282486
doi: 10.1007/164_2021_473
pmc: PMC9281871
mid: NIHMS1822068
doi:
Substances chimiques
Antidepressive Agents
0
Cations
0
Dopamine Plasma Membrane Transport Proteins
0
Organic Cation Transport Proteins
0
Serotonin Plasma Membrane Transport Proteins
0
Serotonin Uptake Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-239Subventions
Organisme : NIMH NIH HHS
ID : R01 MH093320
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1017-23
pubmed: 22806583
Pharmacol Res. 2019 Feb;140:21-32
pubmed: 30423430
Eur Neuropsychopharmacol. 2009 Dec;19(12):868-75
pubmed: 19664909
Neuropsychopharmacology. 2004 Oct;29(10):1790-9
pubmed: 15226739
J Neurosci. 1998 Jul 1;18(13):4854-60
pubmed: 9634551
J Neurochem. 2008 Aug;106(3):1471-82
pubmed: 18513366
Mol Cell Biol. 2003 Nov;23(21):7902-8
pubmed: 14560032
Neuroscience. 2007 Jan 19;144(2):616-22
pubmed: 17110048
Pharmacol Rev. 1999 Dec;51(4):593-628
pubmed: 10581325
Eur J Neurosci. 2018 May 24;:
pubmed: 29797618
J Neurosci. 2004 Mar 17;24(11):2846-51
pubmed: 15028779
J Neurochem. 2015 Dec;135(6):1178-88
pubmed: 26376205
Science. 1996 Nov 29;274(5292):1527-31
pubmed: 8929413
Neuropharmacology. 2006 Jun;50(8):941-52
pubmed: 16581093
Proc Natl Acad Sci U S A. 2009 May 12;106(19):8043-8
pubmed: 19416912
J Neurosci. 2004 Jul 28;24(30):6791-8
pubmed: 15282284
World J Biol Psychiatry. 2006;7(4):198-222
pubmed: 17071541
J Pharm Pharmacol. 1967 May;19(5):335-7
pubmed: 4382408
Eur J Pharmacol. 2019 Jan 5;842:351-364
pubmed: 30473490
Brain Res. 2010 Apr 22;1326:105-13
pubmed: 20171957
Br J Pharmacol. 2002 Jul;136(6):829-36
pubmed: 12110607
Curr Top Behav Neurosci. 2019;43:271-321
pubmed: 30357573
J Neurosci Methods. 2004 Dec 30;140(1-2):169-81
pubmed: 15589347
J Biol Chem. 1998 Dec 4;273(49):32776-86
pubmed: 9830022
Trends Neurosci. 2004 May;27(5):270-7
pubmed: 15111009
J Chem Neuroanat. 2013 Sep;52:36-43
pubmed: 23694905
Pharmacol Rev. 2020 Jan;72(1):253-319
pubmed: 31852803
Pharmacol Ther. 2011 Jul;131(1):61-79
pubmed: 21447358
Am J Psychiatry. 2010 May;167(5):509-27
pubmed: 20231323
Mol Psychiatry. 2015 Jul;20(7):889-900
pubmed: 25092247
Neuroscience. 2007 May 25;146(3):1193-211
pubmed: 17408864
Mol Psychiatry. 2007 Aug;12(8):748-55
pubmed: 17387319
Eur J Pharmacol. 2008 Apr 7;583(2-3):174-85
pubmed: 18282566
Horm Behav. 2009 Jun;56(1):149-57
pubmed: 19371745
J Clin Psychiatry. 1998 Jun;59(6):279-88
pubmed: 9671339
Nicotine Tob Res. 2014 Dec;16(12):1638-46
pubmed: 25143296
Nat Methods. 2014 Jun;11(6):629-32
pubmed: 24776635
Eur J Pharmacol. 2008 Feb 2;580(1-2):135-42
pubmed: 18022153
J Comp Neurol. 2009 Feb 1;512(4):529-55
pubmed: 19025979
Trends Neurosci. 1996 May;19(5):163-71
pubmed: 8723198
CNS Drugs. 2012 Mar 1;26(3):189-204
pubmed: 22303887
Behav Brain Res. 2008 Jan 10;186(1):32-40
pubmed: 17716752
Handb Exp Pharmacol. 2021;266:241-251
pubmed: 34104992
Biol Psychiatry. 2004 Apr 15;55(8):781-4
pubmed: 15050857
Int J Neuropsychopharmacol. 2008 Feb;11(1):35-48
pubmed: 17477885
Mol Psychiatry. 2020 Jun;25(6):1245-1259
pubmed: 31619760
J Antimicrob Chemother. 2019 Apr 1;74(4):1035-1043
pubmed: 30561642
Brain Res. 2009 Mar 19;1261:82-90
pubmed: 19401166
Science. 2003 Jul 18;301(5631):386-9
pubmed: 12869766
Glia. 2017 Aug;65(8):1251-1263
pubmed: 28543680
J Pharmacol Exp Ther. 1970 Nov;175(2):404-18
pubmed: 5481708
Neurosci Lett. 2005 Jul 1-8;382(1-2):195-200
pubmed: 15911148
Handb Exp Pharmacol. 2021;266:41-80
pubmed: 33963461
Handb Exp Pharmacol. 2021;266:81-100
pubmed: 33674913
Pharmacoeconomics. 2007;25(1):7-24
pubmed: 17192115
Brain Res. 2008 Apr 8;1203:68-78
pubmed: 18321472
Drugs. 2012 Jul 9;72(10):1313-33
pubmed: 22731961
J Psychiatry Neurosci. 2002 Jul;27(4):241-7
pubmed: 12174733
J Neurosci. 2006 Aug 23;26(34):8758-66
pubmed: 16928864
J Neurosci. 2010 Nov 10;30(45):15185-95
pubmed: 21068324
J Cereb Blood Flow Metab. 2012 Nov;32(11):1989-2001
pubmed: 22850405
Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):585-94
pubmed: 3222448
Pflugers Arch. 2014 Mar;466(3):517-27
pubmed: 23982114
J Biol Chem. 2013 Feb 1;288(5):3535-44
pubmed: 23255610
Curr Opin Neurobiol. 2015 Feb;30:139-43
pubmed: 25562451
Brain Struct Funct. 2017 May;222(4):1913-1928
pubmed: 27659446
Clin Pharmacol Ther. 2016 Nov;100(5):489-499
pubmed: 27506881
Eur J Pharmacol. 2020 Sep 15;883:173285
pubmed: 32697958
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jan;381(1):33-9
pubmed: 20012264
J Biol Chem. 2004 Nov 26;279(48):50042-9
pubmed: 15448143
ISRN Pharmacol. 2011;2011:161740
pubmed: 22084709
Expert Opin Ther Pat. 2016 Aug;26(8):857-60
pubmed: 27097290
Pharmacol Res. 2019 Feb;140:85-99
pubmed: 30009933
Pharmacol Ther. 2009 Jan;121(1):89-99
pubmed: 19022290
Neuropsychopharmacology. 2018 Nov;43(12):2408-2417
pubmed: 29773909
J Biol Chem. 1997 Apr 18;272(16):10408-13
pubmed: 9099681
Brain Res. 1999 Jun 12;831(1-2):146-54
pubmed: 10411994
Clin Psychol Rev. 2007 Dec;27(8):959-85
pubmed: 17448579
J Neurochem. 1967 May;14(5):489-97
pubmed: 5297947
J Neurochem. 2003 Jan;84(1):43-52
pubmed: 12485400
Br J Psychiatry. 2006 Oct;189:309-16
pubmed: 17012653
J Neural Transm (Vienna). 2009 Jun;116(6):689-97
pubmed: 19280114
Mol Pharmacol. 1998 Aug;54(2):342-52
pubmed: 9687576
Am J Psychiatry. 2004 May;161(5):909-11
pubmed: 15121658
Handb Exp Pharmacol. 2021;266:1-39
pubmed: 33782773
Acta Physiol Scand Suppl. 1964;220:SUPPL 239:1-18
pubmed: 14298286
Pharmacol Biochem Behav. 2015 Apr;131:33-41
pubmed: 25597272
ACS Chem Neurosci. 2013 Jan 16;4(1):16-21
pubmed: 23336039
Glia. 2013 Jun;61(6):905-16
pubmed: 23505051
J Pharmacol Exp Ther. 2013 Aug;346(2):300-10
pubmed: 23709117
J Med Chem. 2013 Sep 26;56(18):7232-42
pubmed: 23984907
Int J Mol Sci. 2020 Oct 14;21(20):
pubmed: 33066466
Handb Exp Pharmacol. 2021;266:199-214
pubmed: 33993413
J Psychiatr Res. 2008 Jul;42(8):605-11
pubmed: 17727882
Mol Cell Biol. 2001 Jul;21(13):4188-96
pubmed: 11390648
Psychopharmacology (Berl). 2019 Jul;236(7):2093-2104
pubmed: 30805668
Handb Exp Pharmacol. 2021;266:119-167
pubmed: 34495395
Synapse. 2011 Oct;65(10):1015-23
pubmed: 21437992
Handb Exp Pharmacol. 2021;266:253-280
pubmed: 33751232
DNA Cell Biol. 1997 Jul;16(7):871-81
pubmed: 9260930
Am J Med Genet. 1999 Feb 5;88(1):83-7
pubmed: 10050973
Br J Pharmacol Chemother. 1965 Aug;25(1):34-49
pubmed: 19108208
FEBS Open Bio. 2017 Jan 09;7(2):237-248
pubmed: 28174689
Eur J Med Chem. 2017 Sep 8;137:476-487
pubmed: 28624702
Mol Psychiatry. 2012 Sep;17(9):926-39
pubmed: 21769100
J Med Chem. 2011 Jul 14;54(13):4548-58
pubmed: 21599003
J Neurosci. 2010 Apr 14;30(15):5357-67
pubmed: 20392957
Brain Res. 2005 Nov 23;1063(1):69-76
pubmed: 16266691
Mol Cell Biol. 2001 Aug;21(16):5471-7
pubmed: 11463829
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18976-81
pubmed: 19033200
J Neurosci. 2013 Jun 19;33(25):10534-43
pubmed: 23785165
Mol Autism. 2014 Aug 13;5:43
pubmed: 25802735
J Neurochem. 2005 Sep;94(5):1427-37
pubmed: 16000150
J Pharmacol Sci. 2010;113(3):263-6
pubmed: 20562519
Pharmacol Res. 2012 Apr;65(4):491-6
pubmed: 22342816
Neuropsychopharmacology. 2010 Jul;35(8):1761-74
pubmed: 20357757
Br J Psychiatry. 2006 Mar;188:210-5
pubmed: 16507960
Nat Neurosci. 1998 Sep;1(5):349-51
pubmed: 10196521
J Neurosci Res. 2003 Mar 1;71(5):701-9
pubmed: 12584728